SUPERNUS PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $60.10 million for the 3-month period ending 2016-09-30, per its 10-K filed 2017-03-16.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2017-03-16
- SUPERNUS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2016-09-30 was $60.10M.
- SUPERNUS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2015 was $1.80M.
- SUPERNUS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2014 was -$10.10M, a 146.76% decline from fiscal 2013.
- SUPERNUS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2013 was $21.60M, a 22.03% increase from fiscal 2012.
- SUPERNUS PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $17.70M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|
| 2016-09-30 | $60.10M 10-K · filed 2017-03-16 | ||
| 2015-12-31 | $1.80M 10-K/A · filed 2017-01-20 | $2.50M 10-K · filed 2016-03-09 | |
| 2014-12-31 | -$10.10M 10-K · filed 2015-03-12 | ||
| 2013-12-31 | $21.60M 10-K · filed 2014-03-21 | ||
| 2012-12-31 | $17.70M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |